Transmission electron microscopy revealing the mechanism of action of photodynamic therapy on Trichomonas vaginalis

Fonseca, Thaisa Helena Silva; Gomes, Jessica M.; Alacoque, Marina; Vannier-Santos, Marcos A.; Gomes, Maria Aparecida; Busatti, Haendel Gonçalves Nogueira Oliveira

doi:10.1016/j.actatropica.2018.11.005

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Type II reactions involve the production of singlet oxygen ( 1 O 2 1 D g ), which is highly reactive. 28,29,49,50 Inactivation of pathogens via photodynamic processes is classified as a type of Photodynamic Therapy (PDT) and poses an attractive and most importantly effective alternative treatment against viruses, [51][52][53][54][55][56] fungi, [57][58][59][60][61][62][63] parasites [64][65][66][67][68] and bacteria. 23,27,37,[69][70][71] Over the last 20 years most of the work towards APDT has been focused on the properties of photosensitisers.…”

Section: Introductionmentioning

confidence: 99%

“…Type II reactions involve the production of singlet oxygen ( 1 O 2 1 Δ g ), which is highly reactive. 28,29,49,50 Inactivation of pathogens via photodynamic processes is classified as a type of Photodynamic Therapy (PDT) and poses an attractive and most importantly effective alternative treatment against viruses, 51–56 fungi, 57–63 parasites 64–68 and bacteria. 23,27,37,69–71…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of the light source in antimicrobial photodynamic therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The role of the light source in antimicrobial photodynamic therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The use of methylene blue and light-emitting diodes was evaluated against MTZsensitive and -resistant T. vaginalis isolates. The in vivo photodynamic therapy occurred through the application of 68.1 J/cm 2 to the vaginal canals of female BALB/c mice after a pre-estrogenization procedure to enable T. vaginalis infection [59]. In addition, a dose of 25 mg/kg per day for four days of compound 2,2 -[α,ω-propadiylbis(oxy-1,3-phenylene)]bis-1H-benzimidazole cured a subcutaneous mouse model infection using T. vaginalis MTZsusceptible and MTZ-refractory isolates, and the efficacy was also determined by in vitro susceptibility assay, presenting an MIC value of 9.0 µM [20].…”

Section: Articles: Synthetic Compoundsmentioning

confidence: 99%

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

et al. 2022

View full text Add to dashboard Cite

The multistep translational science behind new drugs comprehends the entire process through laboratory, clinical, and community observations turned into health interventions. The development of new drug options from discovering targets and leading compounds in basic research for implementing therapeutic guidelines contributes to the emergence of health policies essential for infection control. This review updates the translational research in the scenario of the most common non-viral sexually transmitted infection (STI), trichomoniasis. Paradoxically to its high occurrence, it is considered neglected since notification is not mandatory. It turns into a stable disease with health complications, and receives little emphasis from public health programs to control STI. Although related to curable STIs, the current drugs, metronidazole and tinidazole, present therapeutic failures. The need for new options to treat trichomoniasis is established by basic research studies and patents revealing novel synthetic compounds and natural products presenting anti-Trichomonas vaginalis activities, mainly based on in vitro findings. Clinical trials are still focused on new routes of administration for conventional drugs. In addition, nanotechnology approaches are in their infancy, shedding light on potential possibilities for creating more effective, targeted, and safe delivery systems. Overall, the novel proposed approaches need, in addition to pharmaceutical development and efficacy assessments, to ensure that the quality requirements for their use as medicines are met. It is essential to overcome these issues to cross the “Death Valley” of drug discovery and to advance in the translational science criteria in the trichomoniasis drug development field.

show abstract

“…By systemic injection of a photosensitizer (PS) and then irradiating the lesion site with a specific wavelength of light, the PS in the lesion site can be activated to generate cytotoxic reactive oxygen species (ROS, e.g. singlet oxygen, 1 O 2 ), ultimately destroying tumors through multiple pathways [7][8][9]. To achieve effective PDT, new PS carriers need to be constructed, which can selectively deliver a PS into tumor tissues and generate 1 O 2 under irradiation.…”

Section: Introductionmentioning

confidence: 99%

A photoactivatable antibody–Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy

Pan

Sun

et al. 2021

Biomed. Mater.

View full text Add to dashboard Cite

Photodynamic therapy is a new technology for disease diagnosis and treatment in modern medical clinics. The main advantages of photodynamic therapy are low toxicity and side effects, a wide range of applications, no drug resistance, and no obvious trauma in the treatment process. However, to achieve effective photodynamic therapy, new photosensitizer carriers need to be constructed, which can selectively deliver photosensitizers into tumor tissues. In this work, a photoactivatable antibody–Chlorin e6 conjugate with a dual-function to target tumor tissue and realize cancer photodynamic therapy is constructed. Both in vitro and in vivo experiments indicate that the antibody–Chlorin e6 conjugate has the ability to target tumors rapidly and efficiently, and has the ability to generate reactive oxygen species and kill tumor cells. Overall, this photoactivable antibody–Chlorin e6 conjugate may provide a promising strategy to address the current challenges of cancer photodynamic therapy.

show abstract

Transmission electron microscopy revealing the mechanism of action of photodynamic therapy on Trichomonas vaginalis

Cited by 5 publications

References 43 publications

The role of the light source in antimicrobial photodynamic therapy

The role of the light source in antimicrobial photodynamic therapy

Novel Treatment Approaches to Combat Trichomoniasis, a Neglected and Sexually Transmitted Infection Caused by Trichomonas vaginalis: Translational Perspectives

A photoactivatable antibody–Chlorin e6 conjugate enabling singlet oxygen production for tumor-targeting photodynamic therapy

Contact Info

Product

Resources

About